Organigram (OGI) Stock Price, News & Analysis

Company Overview

Organigram Inc. is a Canadian licensed producer of cannabis products. Organigram focuses on producing exceptional, indoor-grown cannabis for patients and adult recreational consumers, as well as developing global business partnerships.

Key Stats

• Today's Range: C$1.68 to C$1.78
• 50-Day Range: C$1.23 to C$1.78
• 52-Week Range: C$1.20 to C$3.09
• Volume: 199,906 shs
• Average Volume: 218,192 shs
• Market Capitalization: C$237.91 million
• P/E Ratio: 2.81
• Dividend Yield: N/A
• Price Target: C$3.13
• Consensus Rating: Buy

Organigram Stock Analysis - MarketRank™

Organigram scored higher than 85% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Organigram has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on no strong buy ratings, 2 buy ratings, no hold ratings, and no sell ratings.

Upside Potential

Organigram has a consensus price target of C$3.13, representing about 84.9% upside from its current price of C$1.69.

Amount of Analyst Coverage

Organigram has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 3.1 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Organigram is 2.81, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 39.95.

Price to Earnings Ratio vs. Sector

The P/E ratio of Organigram is 2.81, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 271.27.

Price to Earnings Growth Ratio

Organigram has a PEG Ratio of 0.42. PEG Ratios below 1 indicate that a company could be undervalued.

Price to Book Value per Share Ratio

Organigram has a P/B Ratio of 0.47. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for OGI.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Organigram does not currently pay a dividend.

Dividend Growth

Organigram does not have a long track record of dividend growth.

News and Social Media

• Score: 1.9 / 5
• News Sentiment: 0.07

News Sentiment

Organigram has a news sentiment score of 0.07. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.65 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Organigram this week, compared to 1 article on an average week.

Search Interest

Only 3 people have searched for OGI on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 2.9 / 5
• Insider Trading: Acquiring Shares

Net Insider Buying

Over the last three months, insiders have purchased a net C$22,000.00 in company stock, which represents 0.0092% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Organigram insiders have bought more of their company's stock than they have sold. Specifically, they have bought C$22,000.00 in company stock and sold C$0.00 in company stock.

Percentage Held by Insiders

31.32% of the stock of Organigram is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

3.90% of the stock of Organigram is held by institutions.

Industry, Sector and Symbol

• Stock Exchange: TSE
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: TSE:OGI
• CIK: N/A
• Web: www.organigram.ca
• Phone: 844-644-4726
• Fax: N/A
• Employees: 987
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Organigram: C$3.13
• High Price Target: C$3.25
• Low Price Target: C$3.00
• Potential Upside/Downside: +84.9%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): C$0.60
• Trailing P/E Ratio: 2.81
• Forward P/E Ratio: 10.35
• P/E Growth: 0.42
• Net Income: -C$57.23 million
• Net Margins: 28.02%
• Pretax Margin: N/A
• Return on Equity: 21.99%
• Return on Assets: -5.56%

Debt

• Debt-to-Equity Ratio: 6.48
• Current Ratio: 2.61
• Quick Ratio: 2.62

Sales & Book Value

• Annual Sales: C$309.18 million
• Price / Sales: 0.77
• Cash Flow: C$0.44 per share
• Price / Cash Flow: 3.85
• Book Value: C$3.59 per share
• Price / Book: 0.47

Miscellaneous

• Outstanding Shares: 140,775,000
• Free Float: N/A
• Market Cap: C$237.91 million
• Optionable: Not Optionable
• Beta: 1.44